Zydus, RK Pharma enters into an exclusive licensing and commercialisation agreement for a novel 505(b)(2) oncology product for USA market Read more
USFDA grants Orphan Drug Designation (ODD) to Zydus’ Desidustat for treatment of beta-thalassemia Read more
Zydus Lifesciences to Acquire 85.6% of Amplitude Surgical, block acquisition expected by Q3 2025 Read more